Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study.
BMC Health Serv Res
; 21(1): 986, 2021 Sep 18.
Article
in English
| MEDLINE | ID: covidwho-1840980
ABSTRACT
BACKGROUND:
Sars-Cov-2 is a novel corona virus associated with significant morbidity and mortality. Remdesivir and Dexamethasone are two treatments that have shown to be effective against the Sars-Cov-2 associated disease. However, a cost-effectiveness analysis of the two treatments is still lacking.OBJECTIVE:
The cost-utility of Remdesivir, Dexamethasone and a simultaneous use of the two drugs with respect to standard of care for treatment Covid-19 hospitalized patients is evaluated, together with the effect of Remdesivir compared to the base model but based on alernative assumptions.METHODS:
A decision tree for an hypothetical cohort of Covid-19 hospitalized patients, from an health care perspective and a one year horizon is specified. Efficacy data are retrieved from a literature review of clinical trials, whilst costs and utility are obtained from other published studies.RESULTS:
Remdesivir, if health care costs are related to the days of hospitalization, is a cost saving strategy. Dexamethasone is cost effective with an ICER ofCONCLUSION:
We find that the use of Remdesivir and/or Dexamethasone is effective from an economic standpoint.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
BMC Health Serv Res
Journal subject:
Health Services Research
Year:
2021
Document Type:
Article
Affiliation country:
S12913-021-06998-w
Similar
MEDLINE
...
LILACS
LIS